Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 5

Tiotropium Respimat® improves physical functioning in chronic obstructive pulmonary disease

Authors Rau-Berger H, Mitfessel, Glaab T

Published 10 October 2010 Volume 2010:5 Pages 367—373


Review by Single anonymous peer review

Peer reviewer comments 3

Heike Rau-Berger1, Harald Mitfessel2, Thomas Glaab1
1Medical Affairs Germany, Respiratory Medicine, Boehringer Ingelheim Pharma GmbH and Co. KG, Ingelheim; 2Pulmonology Practice, Remscheid, Germany

Aim: This observational study with tiotropium Respimat® was performed in a real-life setting to investigate its effectiveness with regard to physical functioning and tolerability.
Methods: Patients with chronic obstructive pulmonary disease (COPD; n = 1,230; mean age, 65.5 years) received tiotropium 5 µg once daily via Respimat® Soft Inhaler for 6 weeks in an open-label observational study. At baseline and week 6, patients completed the Physical Function subdomain [PF-10] of the Short Form (SF) 36 questionnaire.
Results: Improvement in standardized PF-10 score of ≥10 points was achieved by 61.5% of patients. Mean (SD) standardized PF-10 scores improved by 13.4 (15.9) points, from 49.0 (24.5) to 62.3 points (23.5; P < 0.001). Results in smokers (n = 435) were not significantly different to those in nonsmokers. The general condition of patients improved during treatment. Adverse events were reported by 4.0% of patients and were chiefly respiratory symptoms and dry mouth.
Conclusion: In COPD patients receiving tiotropium Respimat® in daily practice, physical function improved rapidly within 6 weeks of treatment, irrespective of smoking status.

Keywords: COPD, tiotropium, physical function, therapy

Creative Commons License © 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.